Company news

NeuroOne Medical Technologies Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 13, 2023

NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System

November 6, 2023

NeuroOne® to Present at the ThinkEquity Conference on October 19, 2023

October 12, 2023

NeuroOne® to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

August 13, 2023

NeuroOne® to Report Third Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on August 14

August 7, 2023

NeuroOne Medical Technologies Corporation Announces Pricing of Public Offering of Common Stock

July 24, 2023

NeuroOne® Submits 510(k) Application to FDA for OneRF™ Ablation System

June 11, 2023

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode in Robotic Neurosurgery

May 16, 2023

NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11

May 10, 2023

NeuroOne® Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

May 10, 2023

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode Performed at Mayo Clinic

May 9, 2023

NeuroOne® to Present at the Sidoti Micro-Cap Virtual Conference on May 10

May 4, 2023

NeuroOne® Announces U.S. Commercial Launch of Evo® sEEG Electrodes

May 1, 2023

NeuroOne® Successfully Completes Initial Animal Implant of Novel Thin Film Paddle Lead for Spinal Cord Stimulation

March 15, 2023

NeuroOne®#¹⁶⁰;to Participate in the 35th Annual Roth Conference

March 8, 2023

NeuroOne® Awarded U.S. Patent Covering Novel and Proprietary Thin Film Electrode Platform

March 6, 2023

NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

February 13, 2023

NeuroOne® to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14

February 8, 2023

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results

December 21, 2022

NeuroOne® to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide Corporate Update on December 13

December 7, 2022

NeuroOne® Successfully Completes Feasibility Study with its OneRF™ Ablation System

December 5, 2022

NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use

November 29, 2022

NeuroOne® to Ring Nasdaq Stock Market Closing Bell on November 22

November 21, 2022

NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use

October 24, 2022

NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 21, 2022

NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

August 10, 2022

NeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode

August 8, 2022

NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11

August 3, 2022

NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode

August 2, 2022

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode

July 11, 2022

NeuroOne Provides Evo® sEEG Update

May 15, 2022

NeuroOne Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

May 11, 2022

NeuroOne® to Report Second Quarter Fiscal Year 2022 Financial Results on May 12

May 2, 2022

NeuroOne® to Present its Disruptive Next-Generation Diagnostic Electrode Technology at the NobleCon18 Investor Conference on April 20, 2022

April 17, 2022

NeuroOne® Releases Successful Completion of Long-Term Stimulation Tests for its Novel Thin Film Platform Electrode Technology

March 1, 2022

NeuroOne Reports First Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

February 13, 2022

NeuroOne® Medical Technologies Corporation Releases Successful Long-Term Recording Test Data for its Novel Thin Film Platform Electrode Technology

February 7, 2022

NeuroOne Appoints Chad Wilhelmy, as Vice President of Quality Control and Regulatory Affairs

January 17, 2022

NeuroOne Reports Fourth Fiscal Quarter and Full Fiscal Year 2021 Financial Results and Provides Corporate Update

December 14, 2021

NeuroOne® Medical Technologies Corporation Announces Successful Completion of Feasibility Study for Ablation Electrode

September 22, 2021

NeuroOne® Medical Technologies Corporation Receives FDA 510(k) Clearance for its Evo® sEEG Electrode

September 6, 2021

NeuroOne Announces Strategic Partnership with RBC Medical Innovations for Ablation Program

August 22, 2021

NeuroOne Reports Third Quarter Fiscal 2021 Financial Results and Corporate Update

August 12, 2021

NeuroOne Introduces Advisory Board for Ablation Electrode Technology that Records and Ablates Brain Tissue Linked to Seizure Activity

June 1, 2021

NeuroOne Announces Approval for Nasdaq Capital Market Listing; Trading Expected to Commence Tomorrow May 26th, 2021 Under the Symbol NMTC

May 24, 2021

NeuroOne Medical Technologies Corporation Announces Reverse Stock Split as Part of Uplisting Strategy to Major Exchange

March 30, 2021

NeuroOne Medical Technologies Corporation Announces Successful Completion of First Performance Milestone in Zimmer Biomet Agreement

February 22, 2021

NeuroOne Medical Technologies Corporation Closes $12.5 Million Private Placement with Certain Prominent Institutional Investors, Advances Towards Nasdaq Uplisting

January 14, 2021

NeuroOne Medical Technologies Corporation Announces Private Placement

January 11, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.